tirzepatide study once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Study sees potential benefits of

These effects are usually mild to moderate, but they can still meaningfully impact daily comfort and medication adherence

This receptor is a heterodimer composed of TGF type I receptor (TGFBR1) and type II receptor (TGFBR2) subunits

The advisory specifically flags surrogate promotion, including disease awareness campaigns, influencer engagement and digital outreach that may effectively advertise prescription drugs

However, higher-risk patientsincluding those with active gastrointestinal symptoms, recent dose increases, gastroparesis, or obesity with GERDmay be advised to stop once-weekly injectable semaglutide approximately one week before the procedure based on individualized evaluation by their surgical team

Continuity gaps: Remote care creates limited value if records and laboratory results do not reach the wider care team